-

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against The Beauty Health Company (SKIN)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against The Beauty Health Company (“Beauty Health” or the “Company”) (NASDAQ: SKIN). The investigation concerns whether Beauty Health and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

On November 13, 2023, Beauty Health announced its financial results for the third quarter of 2023. The Company reported lower-than-expected U.S. revenue and disclosed $63.1 million in restructuring charges related to device upgrades of early generation Syndeo devices. As a result, the Company announced it would revise its fiscal year 2023 net sales guidance to a range of $385 to $400 million and its fiscal year adjusted EBITDA margin guidance to a range of 5% to 6%, and is suspending its long-term 2025 financial outlook. On this news, the price of Beauty Health shares declined by $2.51 per share, or approximately 64.36%, from $3.90 per share to close at $1.39 on November 14, 2023.

If you purchased or otherwise acquired Beauty Health securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: https://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:SKIN

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

REMINDER: Beyond Meat, Inc. Investors With Significant Losses Must Act By March 24, 2026

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds Beyond Meat, Inc. (“Beyond Meat” or the “Company”) (NASDAQ:BYND) investors of the March 24, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as...

GEMINI SPACE STATION, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Gemini Space Station, Inc. (“Gemini” or the “Company”) (NASDAQ:GEMI). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On September 12, 2025, Gemini conducted its initial public offering, selling 15,937,501 shares...

INVESTOR ALERT: Securities Class Action Filed Against NuScale Power Corporation – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired NuScale Power Corporation (“NuScale” or the “Company”) (NYSE:SMR) securities during the period of May 13, 2025 through November 6, 2025, inclusive (“the Class Period”). If you suffered a loss on your NuScale investments, you have until April 20, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submit...
Back to Newsroom